☆ 4.8 Letter

Convalescent plasma therapy for persistent hepatitis E virus infection

JOURNAL OF HEPATOLOGY (2019)

Journal

JOURNAL OF HEPATOLOGY

Volume 71, Issue 2, Pages 434-438

Publisher

ELSEVIER

DOI: 10.1016/j.jhep.2019.04.008

Keywords

Convalescent plasma; Therapeutics; Hepatitis E virus; Immunocompromised

Categories

Gastroenterology & Hepatology

Funding

NHS Blood and Transplant
MRC [MC_UU_12014/12, MC_UU_12014/1] Funding Source: UKRI

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Gastroenterology & Hepatology

Hepatitis E seroprevalence and viremia rate in immunocompromised patients: a systematic review and meta-analysis

Gustav Buescher, Ann-Kathrin Ozga, Eva Lorenz, Sven Pischke, Jurgen May, Marylyn M. Addo, Thomas Horvatits

Summary: The study aimed to compare the anti-HEV seroprevalence and HEV RNA positivity rate between transplant recipients and HIV patients. Results showed no significant difference in anti-HEV seroprevalence between the two groups, but transplant recipients had a significantly higher rate of HEV-RNA positivity, indicating ongoing infection.

LIVER INTERNATIONAL (2021)

Add to Collection

Article Virology

Unmet Needs for the Treatment of Chronic Hepatitis E Virus Infection in Immunocompromised Patients

Nassim Kamar, Arnaud Del Bello, Florence Abravanel, Qiuwei Pan, Jacques Izopet

Summary: Hepatitis E virus (HEV) is the most prevalent hepatitis virus worldwide that can lead to chronic hepatitis and cirrhosis. In the past decade, there have been advancements in the treatment of chronic hepatitis, but there are still unmet needs, such as optimizing immunosuppression and exploring alternative therapies to ribavirin.

VIRUSES-BASEL (2022)

Add to Collection

Article Medicine, Research & Experimental

Treatment of severe COVID-19 with convalescent plasma in Bronx, NYC

Hyun ah Yoon, Rachel Bartash, Inessa Gendlina, Johanna Rivera, Antonio Nakouzi, Robert H. Bortz, Ariel S. Wirchnianski, Monika Paroder, Karen Fehn, Leana Serrano-Rahman, Rachelle Babb, Uzma N. Sarwar, Denise Haslwanter, Ethan Laudermilch, Catalina Florez, M. Eugenia Dieterle, Rohit K. Jangra, J. Maximilian Fels, Karen Tong, Margarette C. Mariano, Olivia Vergnolle, George Georgiev, Natalia G. Herrera, Ryan J. Malonis, Jose A. Quiroz, Nicholas C. Morano, Gregory J. Krause, Joseph M. Sweeney, Kelsie Cowman, Stephanie Allen, Jayabhargav Annam, Ariella Applebaum, Daniel Barboto, Ahmed Khokhar, Brianna J. Lally, Audrey Lee, Max Lee, Avinash Malaviya, Reise Sample, Xiuyi A. Yang, Yang Li, Rafael Ruiz, Raja Thota, Jason Barnhill, Doctor Y. Goldstein, Joan Uehlinger, Scott J. Garforth, Steven C. Almo, Jonathan R. Lai, Morayma Reyes Gil, Amy S. Fox, Kartik Chandran, Tao Wang, Johanna P. Daily, Liise-anne Pirofski

Summary: Convalescent plasma therapy may be beneficial for COVID-19 patients, especially those under 65 years old. Pretransfusion antibody titers are associated with treatment efficacy.

JCI INSIGHT (2021)

Add to Collection

Article Medicine, General & Internal

COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis

Jonathon W. Senefeld, Massimo Franchini, Carlo Mengoli, Mario Cruciani, Matteo Zani, Ellen K. Gorman, Daniele Focosi, Arturo Casadevall, Michael J. Joyner

Summary: Patients who are immunocompromised have increased risk for morbidity and mortality associated with COVID-19. Transfusion of COVID-19 convalescent plasma is associated with a mortality benefit for these patients.

JAMA NETWORK OPEN (2023)

Add to Collection

Editorial Material Biology

Learning more about hepatitis E virus

Altaira D. Dearborn, Ashish Kumar, Joseph Marcotrigiano

Summary: A domain in the ORF1 polyprotein of the hepatitis E virus, previously believed to be a protease, is actually a zinc-binding domain.

ELIFE (2023)

Add to Collection

Article Oncology

SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin

Andreas Volk, Caroline Covini-Souris, Denis Kuehnel, Christian De Mey, Juergen Roemisch, Torben Schmidt

Summary: Patients with immune deficiencies often receive antibodies from healthy donors as a first line of defense against infections. Research shows that plasma-derived immunoglobulin lots produced between December 2020 and June 2021 have increasing neutralizing activity against SARS-CoV-2 over time.

BIODRUGS (2022)

Add to Collection

Article Immunology

Guidance on the Use of Convalescent Plasma to Treat Immunocompromised Patients With Coronavirus Disease 2019 (COVID-19)

Evan M. Bloch, Daniele Focosi, Shmuel Shoham, Jonathon Senefeld, Aaron A. R. Tobian, Lindsey R. Baden, Pierre Tiberghien, David J. Sullivan, Claudia Cohn, Veronica Dioverti, Jeffrey P. Henderson, Cynthia So-Osman, Justin E. Juskewitch, Raymund R. Razonable, Massimo Franchini, Ruchika Goel, Brenda J. Grossman, Arturo Casadevall, Michael J. Joyner, Robin K. Avery, Liise-anne Pirofski, Kelly A. Gebo

Summary: This viewpoint provides expert guidance on the use of convalescent plasma for treating immunocompromised patients with COVID-19, including indications, dosage, frequency/schedule, and duration of treatment. English summary rating: 8/10

CLINICAL INFECTIOUS DISEASES (2023)

Add to Collection

Review Virology

Convalescent Plasma Transfusion for the Treatment of COVID-19 in Adults: A Global Perspective

Saly Kanj, Basem Al-Omari

Summary: After over a year of the COVID-19 pandemic, healthcare systems worldwide are still struggling with rising cases. The use of convalescent plasma transfusion (CPT) shows potential in reducing the severity and duration of COVID-19 symptoms, but early intervention, donor recruitment, and plasma potency present challenges for scaled-up implementation. More randomized clinical trials are needed to fully assess the risks and benefits of CPT.

VIRUSES-BASEL (2021)

Add to Collection

Article Immunology

Detection of Nonenveloped Hepatitis E Virus in Plasma of Infected Blood Donors

Maria Isabel Costafreda, Silvia Sauleda, Angie Rico, Maria Piron, Marta Bes

Summary: This study found that nonenveloped HEV particles can be detected in the plasma of HEV-infected blood donors, which may pose an additional risk to blood safety. The study also observed a higher proportion of nonenveloped HEV in samples with HEV-positive serology and/or increased levels of liver injury markers.

JOURNAL OF INFECTIOUS DISEASES (2022)

Add to Collection

Review Hematology

COVID-19 convalescent plasma

Aaron A. R. Tobian, Claudia S. Cohn, Beth H. Shaz

Summary: COVID-19 convalescent plasma (CCP) is a treatment option for COVID-19 that works through the mediation of antibodies and is primarily effective for elderly outpatients in the early stages of the disease. However, it is not effective for hospitalized patients with moderate to severe disease. Collection of CCP should be as close as possible to the time and location of the patient.

BLOOD (2022)

Add to Collection

Article Immunology

Characterization of an Anti-Ebola Virus Hyperimmune Globulin Derived From Convalescent Plasma

Jonathan M. Ciencewicki, Andrew S. Herbert, Nadia Storm, Nicole M. Josleyn, Kathleen E. Huie, Lindsay G. A. McKay, Anthony Griffiths, John M. Dye, Todd Willis, Vikram Arora

Summary: This paper describes the manufacturing process of a purified anti-Ebola virus immunoglobulin from pooled convalescent plasma and evaluates its efficacy in antibody potency and an animal model. The results show that the anti-Ebola virus immunoglobulin exhibits significantly enhanced neutralizing activity in both in vitro and in vivo experiments. These findings provide important support for the treatment and prophylaxis of Ebola virus disease.

JOURNAL OF INFECTIOUS DISEASES (2022)

Add to Collection

Article Multidisciplinary Sciences

Functional convalescent plasma antibodies and pre-infusion titers shape the early severe COVID-19 immune response

Jonathan D. Herman, Chuangqi Wang, Carolin Loos, Hyunah Yoon, Johanna Rivera, M. Eugenia Dieterle, Denise Haslwanter, Rohit K. Jangra, Robert H. Bortz, Katharine J. Bar, Boris Julg, Kartik Chandran, Douglas Lauffenburger, Liise-Anne Pirofski, Galit Alter

Summary: The study provides insights into the significant impact of convalescent plasma on modulating humoral responses by focusing on spike/nucleocapsid in recipients.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Virology

Ritonavir Blocks Hepatitis E Virus Internalization and Clears Hepatitis E Virus In Vitro with Ribavirin

Putu Prathiwi Primadharsini, Shigeo Nagashima, Masaharu Takahashi, Kazumoto Murata, Hiroaki Okamoto

Summary: Combination therapy with ritonavir and ribavirin significantly improves the inhibition of hepatitis E virus (HEV) growth, even in cells with robust virus production. This study provides insight into the potential of using drugs that block different steps in the HEV life cycle as a novel treatment strategy for chronic hepatitis E.

VIRUSES-BASEL (2022)

Add to Collection

Article Microbiology

Specific Plasma MicroRNA Signatures Underlying the Clinical Outcomes of Hepatitis E Virus Infection

Maria Costafreda, Silvia Sauleda, Mar Riveiro-Barciela, Angie Rico, Meritxell Llorens-Revull, Susana Guix, Rosa M. Pinto, Albert Bosch, Francisco Rodriguez-Frias, Ariadna Rando, Maria Piron, Marta Bes

Summary: Different outcomes of HEV infection are associated with specific dysregulation of microRNAs, which can serve as biomarkers for HEV infection outcomes and contribute to improving the clinical management of hepatitis E patients. This study provides new insights into HEV pathogenesis and potential targets for antiviral treatments.

MICROBIOLOGY SPECTRUM (2023)

Add to Collection

Article Biochemistry & Molecular Biology

Clearance of the SARS-CoV-2 Virus in an Immunocompromised Patient Mediated by Convalescent Plasma without B-Cell Recovery

Maamoun Basheer, Elias Saad, Orly Laskar, Ofir Schuster, Hagai Rechnitzer, Simona Zisman-Rozen, David Azoulay, Nimer Assy

Summary: This case report presents a patient who had difficulty eradicating the corona virus due to being treated with Rituximab, but the combined use of external anti-viral agents like convalescent plasma successfully helped the patient's immune system to eradicate the virus.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Article Critical Care Medicine

Recovery from Covid-19 critical illness: A secondary analysis of the ISARIC4C CCP-UK cohort study and the RECOVER trial

Ellen Pauley, Thomas M. Drake, David M. Griffith, Louise Sigfrid, Nazir Lone, Ewen M. Harrison, J. Kenneth Baillie, Janet T. Scott, Timothy S. Walsh, Malcolm G. Semple, Annemarie B. Docherty

Summary: This study aimed to compare the prevalence and severity of fatigue in survivors of Covid-19 with non-Covid-19 critical illness and explore potential associations between baseline characteristics and worse recovery. The results showed no significant differences in fatigue prevalence and severity between the two groups initially, but at the recovery stage, Covid-19 patients had lower rates and severity of fatigue. Overall, fatigue symptoms may be less severe after Covid-19 infection.

JOURNAL OF THE INTENSIVE CARE SOCIETY (2023)

Add to Collection

Article Pediatrics

Comparison of UK paediatric SARS-CoV-2 admissions across the first and second pandemic waves

Olivia Swann, Louisa Pollock, Karl A. Holden, Alasdair P. S. Munro, Aisleen Bennett, Thomas C. Williams, Lance Turtle, Cameron J. Fairfield, Thomas M. Drake, Saul N. Faust, Ian P. Sinha, Damian Roland, Elizabeth Whittaker, Shamez N. Ladhani, Jonathan S. Nguyen-Van-Tam, Michelle Girvan, Chloe Donohue, Cara Donegan, Rebecca G. Spencer, Hayley E. Hardwick, Peter J. M. Openshaw, J. Kenneth Baillie, Ewen M. Harrison, Annemarie B. Docherty, Malcolm G. Semple

Summary: This study aimed to investigate the clinical characteristics of hospitalized children and young people with SARS-CoV-2 during the UK's second wave. The results showed that patients in the second wave had lower PEWS, less antibiotic use, and fewer respiratory and cardiovascular support compared to the first wave. However, there was no change in the proportion of patients admitted to critical care. At least 20% of patients in this cohort had asymptomatic/incidental SARS-CoV-2 infection.

PEDIATRIC RESEARCH (2023)

Add to Collection

Article Clinical Neurology

Fewer COVID-19 Neurological Complications with Dexamethasone and Remdesivir

Alexander Grundmann, Chieh-Hsi Wu, Marc Hardwick, J. Kenneth Baillie, Peter J. M. Openshaw, Malcolm G. Semple, Dankmar Bohning, Sarah Pett, Benedict D. Michael, Rhys H. Thomas, Ian Galea

Summary: The objective of this study was to assess the impact of treatment with dexamethasone, remdesivir, or both on neurological complications in acute COVID-19. The study found that treatment with dexamethasone, remdesivir, or both was associated with a lower frequency of neurological complications in hospitalized COVID-19 patients, with the greatest benefit observed in patients who received both drugs together.

ANNALS OF NEUROLOGY (2023)

Add to Collection

Article Immunology

Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial

Paul T. Heath, Eva P. Galiza, David Neil Baxter, Marta Boffito, Duncan Browne, Fiona Burns, David R. Chadwick, Rebecca Clark, Catherine A. Cosgrove, James Galloway, Anna L. Goodman, Amardeep Heer, Andrew Higham, Shalini Iyengar, Christopher Jeanes, Philip A. Kalra, Christina Kyriakidou, Judy M. Bradley, Chigomezgo Munthali, Angela M. Minassian, Fiona McGill, Patrick Moore, Imrozia Munsoor, Helen Nicholls, Orod Osanlou, Jonathan Packham, Carol H. Pretswell, Alberto San Francisco Ramos, Dinesh Saralaya, Ray P. Sheridan, Richard Smith, Roy L. Soiza, Pauline A. Swift, Emma C. Thomson, Jeremy Turner, Marianne Elizabeth Viljoen, Louis Fries, Iksung Cho, Irene McKnight, Greg Glenn, E. Joy Rivers, Andreana Robertson, Katia Alves, Kathy Smith, Seth Toback

Summary: In a phase 3 trial, a 2-dose regimen of the NVX-CoV2373 vaccine provided a high level of protection against asymptomatic, symptomatic, and severe COVID-19 for more than 6 months postvaccination. The vaccine showed 100% efficacy against severe disease and 76.3% efficacy against asymptomatic disease.

CLINICAL INFECTIOUS DISEASES (2023)

Add to Collection

Article Parasitology

Prevalence of Crimean-Congo haemorrhagic fever in livestock following a confirmed human case in Lyantonde district, Uganda

Stella A. Atim, Marc Niebel, Shirin Ashraf, Patrick Vudriko, Steven Odongo, Stephen Balinandi, Peace Aber, Ronald Bameka, Anna R. Ademun, Charles Masembe, Robert Tweyongyere, Emma C. Thomson

Summary: Following a human case of CCHF in Lyantonde district, Uganda, a detailed outbreak investigation in the animal population revealed a high circulation of CCHFV among cattle and goats, increasing the environmental risk for future human infections. Therefore, surveillance programs for CCHF in this area and the Ugandan cattle corridor are recommended to prevent and control further cases.

PARASITES & VECTORS (2023)

Add to Collection

Article Multidisciplinary Sciences

Adeno-associated virus 2 infection in children with non-A-E hepatitis

Antonia Ho, Richard Orton, Rachel Tayler, Patawee Asamaphan, Vanessa Herder, Chris Davis, Lily Tong, Katherine Smollett, Maria Manali, Jay Allan, Konrad Rawlik, Sarah E. McDonald, Elen Vink, Louisa Pollock, Louise Gannon, Clair Evans, Jim McMenamin, Kirsty Roy, Kimberly Marsh, Titus Divala, Matthew T. G. Holden, Michael Lockhart, David Yirrell, Sandra Currie, Maureen O'Leary, David Henderson, Samantha J. Shepherd, Celia Jackson, Rory Gunson, Alasdair MacLean, Neil McInnes, Amanda Bradley-Stewart, Richard Battle, Jill A. Hollenbach, Paul Henderson, Miranda Odam, Primrose Chikowore, Wilna Oosthuyzen, Meera Chand, Melissa Shea Hamilton, Diego Estrada-Rivadeneyra, Michael Levin, Nikos Avramidis, Erola Pairo-Castineira, Veronique Vitart, Craig Wilkie, Massimo Palmarini, Surajit Ray, David L. Robertson, Ana da Silva Filipe, Brian J. Willett, Judith Breuer, Malcolm G. Semple, David Turner, J. Kenneth Baillie, Emma C. Thomson

Summary: An investigation found a possible association between AAV2 infection and host genetics in a recent outbreak of acute hepatitis in children in Scotland. The study used various methods to detect AAV2 infection in plasma and liver samples, and identified pathological features related to the virus in liver biopsy samples.

NATURE (2023)

Add to Collection

Article Immunology

Circulation of Lassa virus across the endemic Edo-Ondo axis, Nigeria, with cross-species transmission between multimammate mice

Adetunji Samuel Adesina, Akinlabi Oyeyiola, Adeoba Obadare, Joseph Igbokwe, Chukwuyem Abejegah, Patience Akhilomen, Umaru Bangura, Danny Asogun, Ekaete Tobin, Olufemi Ayodeji, Omolaja Osoniyi, Chris Davis, Emma C. Thomson, Meike Pahlmann, Stephan Guenther, Elisabeth Fichet-Calvet, Ayodeji Olayemi

Summary: We compared the genetic sequences of the Lassa virus obtained from rodents in different localities in Edo and Ondo States, Nigeria. We found different clades of the virus in different areas, suggesting east-west virus migration within the region. The amplification of the virus in certain localities, the spread of rodent-borne variants in larger towns, and the exchange of the virus between different rodent species pose a constant zoonotic threat in the Lassa fever belt.

EMERGING MICROBES & INFECTIONS (2023)

Add to Collection

Review Biology

Emerging Rhabdoviruses and Human Infection

James G. Shepherd, Chris Davis, Daniel G. Streicker, Emma C. Thomson

Summary: Rhabdoviridae is a large viral family, and while Rabies lyssavirus is the main cause of human rabies, there are other rhabdoviruses that can also infect humans. Next-generation sequencing technology has led to the discovery of new rhabdoviruses, but there is still much we don't know about their impact on human health.

BIOLOGY-BASEL (2023)

Add to Collection

Article Medicine, Research & Experimental

Feasibility and acceptability of an evidence-informed digital intervention to support self-management in people with non-alcoholic fatty liver disease: protocol for a non-randomised feasibility study (VITALISE)

Leah Avery, Hollie Smith, Stuart McPherson, Kate Hallsworth

Summary: This study aims to evaluate the feasibility and acceptability of a NAFLD-specific digital lifestyle intervention (VITALISE) in a secondary care clinical setting. The intervention is designed to target changes in dietary and physical activity behaviors of patients with NAFLD to initiate weight loss and weight loss maintenance. The study plans to recruit 35 patients with newly diagnosed NAFLD and assess the feasibility and acceptability of VITALISE.

PILOT AND FEASIBILITY STUDIES (2023)

Add to Collection

Article Medicine, Research & Experimental

1 2 3 4 5678 9 10 11 12Universite de Lorraine, CHRU-Nancy, Service des Maladies Infectieuses etTropicales, Nancy, France 13U 1415 16 17 18

Bronner P. Goncalves, Waasila Jassat, Joaquin Baruch, Madiha Hashmi, Amanda Rojek, Abhishek Dasgupta, Ignacio Martin-Loeches, Luis Felipe Reyes, Chiara Piubelli, Barbara Wanjiru Citarella, Christiana Kartsonaki, Benjamin Lefevre, Jose W. Lopez Revilla, Miles Lunn, Ewen M. Harrison, Moritz U. G. Kraemer, Sally Shrapnel, Peter Horby, Zeno Bisoffi, Piero L. Olliaro, Laura Merson

Summary: Vaccinated and unvaccinated COVID-19 patients may differ in clinical presentation and comorbidities, with significant between-country variation.

MED (2023)

Add to Collection

Article Public, Environmental & Occupational Health

Geographical variation in hepatitis C-related severe liver disease and patient risk factors: a multicentre cross-sectional study

Sema Nickbakhsh, E. Carol McWilliam Leitch, Shanley Smith, Chris Davis, Sharon Hutchinson, William L. L. Irving, John McLauchlan, Emma C. C. Thomson

Summary: A study on 3829 HCV-positive patients in England and Scotland reveals that age, gender, weight, diabetes, virus genotype, infection route, and ethnicity are associated with the risk of severe liver disease. This study provides baseline data for monitoring HCV-related disease burden and designing risk prevention measures.

EPIDEMIOLOGY AND INFECTION (2023)

Add to Collection

Article Infectious Diseases

Ledipasvir/sofosbuvir and ribavirin for the treatment of ribavirin-refractory persistent hepatitis E virus infection

Jennifer Gallacher, Yusri Taha, Ana da Silva Filipe, Samreen Ijaz, Stuart McPherson

Summary: This case report demonstrates the effectiveness of ledipasvir/sofosbuvir and ribavirin in treating ribavirin-refractory persistent hepatitis E virus infection. The patient showed a sustained viral response and clearance of the virus in blood and stool.

IDCASES (2023)

Add to Collection

Article Biotechnology & Applied Microbiology

The P323L substitution in the SARS-CoV-2 polymerase (NSP12) confers a selective advantage during infection

Hannah Goldswain, Xiaofeng Dong, Rebekah Penrice-Randal, Muhannad Alruwaili, Ghada T. Shawli, Tessa Prince, Maia Kavanagh Williamson, Jayna Raghwani, Nadine Randle, Benjamin Jones, I'ah Donovan-Banfield, Francisco J. Salguero, Julia A. Tree, Yper Hall, Catherine Hartley, Maximilian Erdmann, James Bazire, Tuksin Jearanaiwitayakul, Malcolm G. Semple, Peter J. M. Openshaw, J. Kenneth Baillie, Stevan R. Emmett, Paul Digard, David A. Matthews, Lance Turtle, Alistair C. Darby, Andrew D. Davidson, Miles W. Carroll, Julian A. Hiscox

Summary: The mutational landscape of SARS-CoV-2 varies between the dominant viral genome sequence and minor genomic variant population. The emergence of D614G substitution in the spike protein is associated with increased transmissibility. The P323L substitution in the viral polymerase is also observed, but not under strong selective pressure.

GENOME BIOLOGY (2023)

Add to Collection

Article Multidisciplinary Sciences

Liver injury in hospitalized patients with COVID-19: An International observational cohort study

Bharath Kumar Tirupakuzhi Vijayaraghavan, Saptarshi Bishnu, Joaquin Baruch, Barbara Wanjiru Citarella, Christiana Kartsonaki, Aronrag Meeyai, Zubair Mohamed, Shinichiro Ohshimo, Benjamin Lefevre, Abdulrahman Al-Fares, Jose A. Calvache, Fabio Silvio Taccone, Piero Olliaro, Laura Merson, Neill K. J. Adhikari, ISARIC Clinical Characterisation Grp

Summary: Using a large dataset, this study evaluated the prevalence and severity of liver enzyme abnormalities in COVID-19 patients and found that these abnormalities are associated with worse outcomes.

PLOS ONE (2023)

Add to Collection

Meeting Abstract Gastroenterology & Hepatology

Aetiology and outcomes of cirrhosis and hepatocellular carcinoma in Blantyre, Malawi

Alexander Stockdale, Benno Kreuels, Isaac Shawa, Niza Silungwe, Karen Chetcuti, Elizabeth Joekes, Blessings Mbale, Jane Mallewa, Egbert Tannich, Christina Weiler-Normann, Marc Lueetgehetman, Peter Finch, Emma Thomson, Anna Maria Geretti, Melita Gordon

GUT (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.